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Abstract
In the United States, over 200,000 new patients are diagnosed with abdominal aortic aneurysm 
(AAA) each year. Consequently, over 40,000 highly morbid aortic reconstructions are performed 
each year to prevent aneurysm rupture, a catastrophic event associated with near-certain mortality. 
No pharmaceutical currently exists to slow aneurysm growth, but a 50% reduction in diameter 
growth per annum could halve the number of aortic reconstructions required. Therefore, successful 
use of cell therapy to modulate chronic inflammation hallmark to AAA to slow diameter 
expansion represents a potentially paradigm-altering treatment.
There continues to be no U.S. Food and Drug-approved medication to slow or stop AAA 
growth. This deficit is certainly not due to a lack of effort over the previous decades. Initial 
investigations focused on the reduction of mechanical stress through decreasing blood 
pressure and sac pressurization cycles; however, clinical trials investigating drugs such as 
angiotensin II converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), 
and beta blockers all failed to demonstrate a therapeutic reduction of diameter growth 
compared to placebo. Next, the inhibition of matrix metalloproteinases (MMP) was trialed 
with doxycycline, an antibiotic inhibitor of MMP-2 and -9. Doxycycline also treats species 
of Chlamydia which were isolated from the aortic walls of a minority of aneurysmal arteries. 
While initial uncontrolled results were promising, therapeutic response was not replicated in 
large randomized studies. Lastly, aortic wall inflammation was targeted using statins, a 
ubiquitous anti-inflammatory, lipid lowering drug to limited success. The discovery of a 
nonsurgical treatment for AAA is contingent on the robust understanding of disease 
pathogenesis, which continues to be nebulous at best.
AAA risk factors such as tobacco abuse, advancing age, uncontrolled hypertension, male 
gender, and Caucasian ethnicity have all been well described but fail to provide evidence 
elucidating pathogenesis. Regardless, existing evidence implicates that disease initiation is 
multifactorial with a strong genetic element. There has been a focus of late toward the role 
of autoimmune mechanisms in AAA formation. The characterization of aortic wall 
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inflammation consisting of mononuclear infiltrates, immunoglobulins, cytokines, and 
proteases implicate both a host innate and adaptive response. Of note, concentrations of 
CD4+ T cells have been recently discovered in the periadventitial VALT (vascular associated 
lymphatic tissue) expressing identical T cell receptors, against a currently unknown antigen, 
and therefore clonally expanded, providing crucial evidence for AAA as an autoimmune 
disease.1 Moreover, IL-17, a cytokine elaborated from the antigen-specific Th17 lymphocyte 
and overexpressed in autoimmune disorders, is highly expressed in the AAA condition. 
Abrogation of this cytokine, in animal models, have demonstrated efficacy in decreasing 
aneurysm diameter growth.2 Although several putative autoantigens have been proposed, the 
true causative antigen has yet to be identified.3
We believe aneurysm initiation can be divided into two stages: sensitization followed by 
chronic inflammation. In the sensitization phase, elastin from the lung is broken down to 
small antigenic fragments secondary to injury, often from cigarette smoke exposure and 
explaining the high risk of AAA formation in those with a significant pack-year history.4 
These previously hidden elastin antigens are key to the progression of COPD severity by 
recruiting additional inflammatory cells, driving its own upregulation; it also promotes 
polarization towards the M1 pro-inflammatory macrophage sensitized to elastin-rich tissues 
such as the aortic wall.5 Not surprisingly, in serum of patients with AAA compared to risk-
factor matched non-AAA controls, we found a significant elevation in IgGs reactive to 
aortic-derived elastin.6
In the inflammation stage, self-sensitized mononuclear cells hone to the infrarenal aorta, a 
relatively weak section of a large elastic artery prone to excessive mechanical stress 
secondary to the tapered configuration and shear stress introduced by the aortic bifurcation, 
exposing previously hidden self-antigens.7 Additionally, the infrarenal segment is relatively 
devoid of vascular smooth muscle cells and elastin lamellae in the tunica media, magnifying 
the impact of any structural damage. Small human aortic aneurysm surgical specimens are 
histologically characterized by this inflammatory infiltrate which is largely absent from 
healthy aortic wall. The dominant cell populations are B and T lymphocytes along with 
smaller populations of macrophages, mast cells, and NK cells. The elaboration of cytokines 
such as IL-2, IFNγ, and TNFα by a predominantly Th1 mononuclear response stimulates 
pro-inflammatory osteopontin (OPN) secretion from macrophages and vascular smooth 
muscle cells further propagating the inflammatory response.8 OPN has been shown to be a 
strong stimulus for monocyte and lymphocyte chemotaxis, prolongs lymphocyte survival, 
enhances cell mediated immunity, and polarizes towards the M1 macrophage.9
Not all smokers suffer from aneurysmal degeneration of their aortic wall. In our 
investigations, we found a unique deficiency of the CD4+CD49b+LAG3+ Tr1 lymphocyte in 
the AAA patient which was not present in the circulation of risk-factor matched non-AAA 
subjects. This antigen-specific regulatory T lymphocyte primarily elaborates IL-10, a potent 
anti-inflammatory cytokine in response to antigen recognition.10 Not only was this Tr1 
population depleted, but it was also less functional in terms of ability to migrate to a 
stimulus, secrete IL-10 when activated, and polarize monocytes towards the anti-
inflammatory M2 macrophage. Therefore, we hypothesized that this deficit of IL-10 and 
Tr1, and inability control aortic wall inflammation, may be the driver for initial aortic ectasia 
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and eventual aneurysm formation. The reason for the depletion is unclear to us presently. 
However, we hypothesize it may be related to gene suppression via DNA methylation or 
miRNA interference. In fact, we observed an elevation in miR-15a, miR-27a, and miR-92a, 
miRNAs known to inhibit IL-10 expression in the plasma of AAA patients.
While chronic inflammation drives initial aortic ectasia and dilation, wall tension consistent 
with the Law of Laplace becomes the predominant force as the aneurysm continues to 
expand. When wall tension drives sac expansion, pharmaceutical therapy is no longer an 
option in AAA treatment and surgical aortic reconstruction is required. Therefore, any 
pharmaceutical intervention must target the AAA while diameter is still conserved and 
before wall tension overwhelmingly drives sac expansion. The early identification of 
patients at risk of AAA development is crucial to the success of nonsurgical treatment. Our 
preliminary investigations into Tr1 and Th17 expression in the AAA condition have 
suggested that the ratio between the two may be an accurate predictor of aneurysm presence; 
however, more studies need to be completed to determine whether this bears out.
Mesenchymal stem cells (MSCs) do not constitutively express MHC-II and therefore 
represents a potential source of allogeneic donor cells. Although this physiology of this cell 
population is poorly understood at present, previous studies has shown tissue reparative 
activity with intravenous infusions of MSCs in the heart, pancreas, and brain undergoing 
ischemic injury.11 In our experiments, we found that MSCs, once activated with TNFα, 
displayed a unique ability to induce the Tr1 lymphocyte in vitro through an IL-10 dependent 
mechanism. Additionally, this induction ability was not cell-cell contact dependent as it 
occurred even with isolation of MSCs and naïve T-cells on either sides of a transwell 
membrane. In experiments in the mouse topical elastase AAA model, we observed that 
human MSCs increased Treg (an antigen nonspecific CD4+ IL-10 expressing regulatory cell) 
suppressor function, increased aortic wall Treg counts, and inhibited overall AAA growth 
over time. Additionally, total IL-10 expression in circulation increased 12-fold over that of 
controls. Interestingly, mouse IL-10 continued to be elevated over time and continued to 
peak at day 21 (when the experiment was terminated), even as treatment MSCs were cleared 
by day 3, suggesting a lasting therapeutic response.
In early 2017, we began enrollment for the phase I ARREST trial (Aortic aneuRysm 
Repression with mEsenchymal STem cells) targeting patients with small aortic aneurysms 
(35-45 mm), the only study of its kind.12 These potential participants are identified through 
U.S. Preventative Task Force recommended AAA sonographic screenings for patients aged 
65, an exam provided for no cost as a part of the “Welcome to Medicare” package. In this 
study, 36 patients are randomized at a 1:1:1 ratio to placebo, 1 × 106 MSCs/kg, or 3 × 106 
MSCs/kg through a large bore peripheral IV and followed for five years to determine 
changes in aortic diameter, cytokine expression, and circulating immune cell expression. The 
aim of treatment is to shift the inflammatory environment of AAA towards that of immune 
regulation which is observed in the risk-factor matched cohort. We hypothesize that MSC 
administration will increase Tr1 and Treg suppressor function in a dose dependent manner 
and upregulate overall IL-10 expression. Currently, seven patients have been enrolled and 
treated per protocol. Thus far, very preliminary results support an increase in the Tr1:Th17 
ratio in response to MSC infusion.
Wang and Murphy Page 3
Circ Res. Author manuscript; available in PMC 2019 March 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Certainly, challenges with cell therapy have presented themselves as the ARREST trial 
continues to mature. One of which is finding a steady supply of clinical grade MSCs. These 
cells must be harvested from the iliac crests of healthy donors, proliferated, and 
administered at an early passage to ensure consistency and quality. Several times, enrollment 
was paused secondary to a poor supply of treatment product. Additionally, the treatment 
product is limited by the possibility of host rejection and hypersensitivity response. 
Therefore, the MSC exosome represents a particularly interesting treatment product. The 
exosome is a secreted extracellular vesicle containing mRNA, miRNA, and proteins which 
incorporates into the target cell membrane to deliver its products to modulate gene 
expression. MSC exosomes isolated from conditioned media has demonstrated efficacy in 
multiple animal disease models and could potentially represent a more optimal treatment 
product for small AAA. It is our belief that non-cellular treatment products, such as 
exosomes, represents the future in this field as it voids many safety concerns and ensures a 
homogeneous treatment product.
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